Objective: Von Hippel-Lindau (VHL) syndro- me is the most common genetic-based hereditary kidney tumor syndrome. Preserving renal function is important while obtaining oncological survival at this syndrome in which recurrent kidney tumors exist. In this study, the management of kidney tu- mors in VHL Syndrome was examined by evalua- ting a VHL family originated from same pedigree.
Material and Methods: In this study, 18 in- dividuals originated from an autosomal dominant inherited VHL syndrome family whose kidney tu- mors were managed in our department between Ja- nuary 2005 and December 2018 were investigated. The demographics, clinical oncological and renal functional parameters were retrospectively evalua- ted. Cancer free survival was defined as the absence of cyst or/and tumor in two kidneys or the presence of cyst or/and tumor less than 3 cm those need no intervention. Cancer specific survival was defined as death related to kidney cancer while overall sur- vival was death from any cause other than cancer. Estimated glomerular filtration rate (eGFR) was calculated using Modification and Diet in Renal Disease (MDRD) formula. Patients were evaluated in three groups according to their generation. As the number of cases is small, descriptive statistical methods were used without performing any com- parative statistical methods.
Results: The median patient age at the diag- nosis was 38 years and it was 49, 43.5 and 24 years for first, second and third generation, respecti- vely. A total of 21 kidney tumor operations were performed in 10 (55.6%) patients. 14 (66.7%) and7 (33.3%) of those operations were nephron sparing partial and radical nephrectomies, respectively. Estimated 10 years cancer free-, cancer specific- and overall survivals for overall cohort were 37.3%, 84.0% and 84.0%, respectively. These outcomes were found 66.7%, 66.7% and 66.7%for first generation, 40%, 90% and 90% for second generation and 80%, 100% and 100% for third generation, respectively. Median eGFR for ove- rall cohort was 61 mL/min/1.73m2 while it was found 38, 60 and 107 mL/min/1.73m2 for first, second and third generations, respectively. A total of 2 (11.1%) patients received renal replacement treatment inclu- ding 1 renal transplantation (5.6%) in first generation and 1 hemodialysis (5.6%) in second generation.
Conclusion: With appropriate follow-up and treatment protocols, it seems that sparing renal functions without need for renal replacement treatments is possible while providing oncological control for kidney tu- mors in Von Hippel-Lindau Syndrome.
Keywords: Von Hippel-Lindau Syndrome, Kidney Tumor, Treatment
Abstract
Objective: Von Hippel-Lindau (VHL) syndro- me is the most common genetic-based hereditary kidney tumor syndrome. Preserving renal function is important while obtaining oncological survival at this syndrome in which recurrent kidney tumors exist. In this study, the management of kidney tu- mors in VHL Syndrome was examined by evalua- ting a VHL family originated from same pedigree.
Material and Methods: In this study, 18 in- dividuals originated from an autosomal dominant inherited VHL syndrome family whose kidney tu- mors were managed in our department between Ja- nuary 2005 and December 2018 were investigated. The demographics, clinical oncological and renal functional parameters were retrospectively evalua- ted. Cancer free survival was defined as the absence of cyst or/and tumor in two kidneys or the presence of cyst or/and tumor less than 3 cm those need no intervention. Cancer specific survival was defined as death related to kidney cancer while overall sur- vival was death from any cause other than cancer. Estimated glomerular filtration rate (eGFR) was calculated using Modification and Diet in Renal Disease (MDRD) formula. Patients were evaluated in three groups according to their generation. As the number of cases is small, descriptive statistical methods were used without performing any com- parative statistical methods.
Results: The median patient age at the diag- nosis was 38 years and it was 49, 43.5 and 24 years for first, second and third generation, respecti- vely. A total of 21 kidney tumor operations were performed in 10 (55.6%) patients. 14 (66.7%) and7 (33.3%) of those operations were nephron sparing partial and radical nephrectomies, respectively. Estimated 10 years cancer free-, cancer specific- and overall survivals for overall cohort were 37.3%, 84.0% and 84.0%, respectively. These outcomes were found 66.7%, 66.7% and 66.7%for first generation, 40%, 90% and 90% for second generation and 80%, 100% and 100% for third generation, respectively. Median eGFR for ove- rall cohort was 61 mL/min/1.73m2 while it was found 38, 60 and 107 mL/min/1.73m2 for first, second and third generations, respectively. A total of 2 (11.1%) patients received renal replacement treatment inclu- ding 1 renal transplantation (5.6%) in first generation and 1 hemodialysis (5.6%) in second generation.
Conclusion: With appropriate follow-up and treatment protocols, it seems that sparing renal functions without need for renal replacement treatments is possible while providing oncological control for kidney tu- mors in Von Hippel-Lindau Syndrome.
Keywords: Von Hippel-Lindau Syndrome, Kidney Tumor, Treatment